Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MME | P08473 | 3/20 | 0.51 |
| ▸ | MMP2 | P08253 | 2/20 | 0.48 |
| ▸ | CTRB1 | P17538 | 1/20 | 0.44 |
| ▸ | HPGD | P15428 | 1/20 | 0.44 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.43 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.43 |
| ▸ | ATM | Q13315 | 1/20 | 0.43 |
| ▸ | CPA1 | P15085 | 1/20 | 0.43 |
| ▸ | NPC1 | O15118 | 1/20 | 0.42 |
| ▸ | RAB9A | P51151 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7607678 | 0.84 | MAPK1 (0.60) | MMECTRB1HPGDCYP3A4MAPK1 | |
| SCHEMBL7411780 | 0.84 | MAPK1 (0.60) | MMECTRB1HPGDCYP3A4MAPK1 | |
| SCHEMBL15670498 | 0.81 | ALDH1A1 (0.59) | MMEMMP2CTRB1HPGDCYP3A4 | |
| SCHEMBL17138022 | 0.81 | ALDH1A1 (0.59) | MMEMMP2CTRB1HPGDCYP3A4 | |
| SCHEMBL11884009 | 0.77 | CTRB1 (0.49) | MMEMMP2CTRB1CYP3A4MAPK1 | |
| SCHEMBL30222482 | 0.77 | MME (0.47) | MMEHPGDCYP3A4MAPK1NPC1 | |
| SCHEMBL6427433 | 0.76 | MME (0.59) | MMECPA1 | |
| SCHEMBL6427435 | 0.76 | MME (0.59) | MMECPA1 | |
| Acetic Acid SCHEMBL28551793 | 0.75 | MME (0.45) | MMECTRB1HPGDCYP3A4MAPK1 | |
| SCHEMBL23151859 | 0.73 | BCAT2 (0.50) | MMEMMP2CTRB1CYP3A4MAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 166 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240148882-A1 | METHODS OF TREATING AN OCULAR DISEASE OR DISORDER | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2024-05-09 | — | — | US | disclosed |
| US-11723982-B2 | Methods of treating an ocular disease or disorder | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2023-08-15 | — | — | US | disclosed |
| US-20220265763-A1 | POLYPEPTIDE-POLYMER CONJUGATES AND METHODS OF USE THEREOF | UNIV CALIFORNIA (US) | 2022-08-25 | — | — | US | disclosed |
| US-20220227855-A1 | COMPOSITIONS AND METHODS FOR TREATMENT OF ANGIOGENESIS RELATED DISEASES | THE UNIVERSITY OF MASSACHUSETTS | 2022-07-21 | — | — | US | disclosed |
| EP-3386520-B1 | METHODS OF TREATING AN OCULAR DISEASE OR DISORDER | UNIV CALIFORNIA (US) | 2022-07-20 | — | — | EP | disclosed |
| US-11291707-B2 | Polypeptide-polymer conjugates and methods of use thereof | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2022-04-05 | — | — | US | disclosed |
| US-20210113655-A1 | POLYPEPTIDE-POLYMER CONJUGATES AND METHODS OF USE THEREOF | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2021-04-22 | — | — | US | disclosed |
| US-20210113702-A1 | METHODS OF TREATING AN OCULAR DISEASE OR DISORDER | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2021-04-22 | — | — | US | disclosed |
| WO-2020219497-A1 | COMPOSITIONS AND METHODS FOR TREATMENT OF ANGIOGENESIS RELATED DISEASES | THE UNIVERSITY OF MASSACHUSETTS (US) | 2020-10-29 | — | — | WO | disclosed |
| US-10765759-B2 | Methods of treating an ocular disease or disorder | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2020-09-08 | — | — | US | disclosed |
| US-20040132640-A1 | Glycopegylation methods and proteins/peptides produced by the methods | NEOSE TECHNOLOGIES, INC. | 2004-07-08 | — | — | US | disclosed |
| US-20040126838-A1 | Follicle stimulating hormone: remodeling and glycoconjugation of FSH | NEOSE TECHNOLOGIES, INC. | 2004-07-01 | — | — | US | disclosed |
| US-20040115168-A1 | Interferon beta: remodeling and glycoconjugation of interferon beta | NEOSE TECHNOLOGIES, INC. | 2004-06-17 | — | — | US | disclosed |
| US-20040082026-A1 | Interferon alpha: remodeling and glycoconjugation of interferon alpha | NEOSE TECHNOLOGIES, INC. | 2004-04-29 | — | — | US | disclosed |
| US-20040077836-A1 | Granulocyte colony stimulating factor: remodeling and glycoconjugation of G-CSF | NEOSE TECHNOLOGIES, INC. | 2004-04-22 | — | — | US | disclosed |
| US-20040063911-A1 | Protein remodeling methods and proteins/peptides produced by the methods | NEOSE TECHNOLOGIES, INC. | 2004-04-01 | — | — | US | disclosed |
| US-20040043446-A1 | Alpha galalctosidase a: remodeling and glycoconjugation of alpha galactosidase A | NEOSE TECHNOLOGIES, INC. | 2004-03-04 | — | — | US | disclosed |
| US-20040001892-A1 | Tunable, semi-interpenetrating polymer networks (sIPNS) for medicine and biotechnology | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2004-01-01 | — | — | US | disclosed |
| US-5965106-A | ADMINISTERING TARGETING MOIETY COUPLED TO AFFINITY COMPONENT, WHEREIN TARGETING MOIETY HAS AFFINITY FOR BINDING SITES IN TARGET AREA, AND BINDING PARTNER TO AFFINITY COMPONENT COUPLED TO FUNCTIONAL MOIETY TO LOCALIZE FUNCTIONAL MOIETY IN TARGET | PERIMMUNE HOLDINGS, INC. (US) | 1999-10-12 | — | — | US | disclosed |
| US-4202775-A | CROSSLINKABLE ETHYLENICALLY UNSATURATED POROUS COPOLYMER | ASAHI KASEI KOGYO KABUSHIKI KAISHA (JP) | 1980-05-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040077836-A1 | Granulocyte colony stimulating factor: remodeling and glycoconjugation of G-CSF | CSF3R, CSF1R, GMFG | MME 923/4885MMP2 1010/4885CTRB1 2873/4885 |
| US-20040082026-A1 | Interferon alpha: remodeling and glycoconjugation of interferon alpha | IFNG, IFNAR1, IRF3 | MME 640/4885MMP2 1520/4885CTRB1 3331/4885 |
| US-20040063911-A1 | Protein remodeling methods and proteins/peptides produced by the methods | PTMS, ANPEP, SMURF1 | MME 132/4885MMP2 646/4885CTRB1 1957/4885 |
| US-20040132640-A1 | Glycopegylation methods and proteins/peptides produced by the methods | PTMS, ANPEP, NGLY1 | MME 112/4885MMP2 1364/4885CTRB1 2298/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.